Healthcare, competitiveness, innovation and simplification
News
20 May 2026
Healthcare, simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Biotechnology

The Biotech Act can strengthen Europe’s biotechnology ecosystem by making regulatory pathways more efficient and improving coordination at EU level. It can also support the responsible use of data and AI in research and manufacturing. These improvements will only have an impact if they are implemented consistently and work in practice for companies operating across several Member States.

Europe also needs incentives that match the scale and risk of biotechnology investment. A strengthened supplementary protection certificate extension would help ensure that faster procedures lead to more research, clinical activity and manufacturing in Europe. The framework should remain science based and open to international cooperation, while supporting diverse supply chains and the skills needed for long-term competitiveness.

Medical technology

The targeted revision of the MDR and IVDR is a welcome step toward a more workable medical technology framework. It would replace rigid certification cycles with risk-based reviews and make certain post-certification changes easier to manage. By recognising real-world evidence and creating clearer routes for breakthrough devices, the proposal would strengthen Europe’s position as a launch market for medical technologies.

Further changes would give companies greater certainty and better support innovation. Policymakers should clarify the rules for drug device combination products and ensure that reprocessing rules keep patient safety at the centre. Labelling changes should remain subject to appropriate oversight. Health institution exemptions should also be carefully balanced so they do not weaken patient safeguards or distort competition.

The MDR and IVDR must also align properly with wider EU legislation, including the AI Act and cybersecurity rules. Clearer timelines and a single reporting approach would help avoid duplication. A more flexible framework would make Europe a more attractive place to launch medical technologies and improve patient access across the EU.

Related items

News
29 Sep 2026

Building trust without slowing innovation

At RAID 2026, Thibaut L’Ortye, Chief Policy and Public Affairs Officer, AmCham EU joined a panel discussion on EU-US regulatory approaches to technology. Taking place on Tuesday, 29 September 2026, the discussion explored how transatlantic cooperation can focus on shared outcomes rather than identical rulebooks, including on cybersecurity, AI safety, consumer protection and resilient supply chains. Mr L’Ortye also highlighted the wider conditions needed to strengthen Europe’s competitiveness.

Industry
Simplification
Read more
Read more about Building trust without slowing innovation
Position Paper
24 Sep 2026

Gold-plating in practice

"Gold-plating" of EU legislation has become a structural challenge for companies operating across the Single Market. While Member States are often permitted to introduce additional national measures when implementing EU law, these divergences frequently create fragmented compliance requirements, administrative burdens and increased costs for businesses.

Drawing on examples from AmCham EU member companies across digital policy, cybersecurity, data protection, telecommunications, environmental regulation, consumer protection, tax transparency and labour law, the paper shows how national additions to EU rules can result in parallel compliance systems, duplicate reporting obligations, country-specific product adaptations and barriers to cross-border operations.

The paper highlights four key findings:

  • Divergence between Member States is often a bigger cost driver than any single regulatory requirement.

  • Fragmentation extends beyond directive transposition and also arises through opening clauses, national guidance, administrative practices and regional measures.

  • Minimum-harmonisation legislation can still create significant Single Market fragmentation.

  • Gold-plating occurs at both national and sub-national levels.

The European Commission should address these issues through greater consistency in implementation, increased transparency around national additions, reduced duplication in reporting and registration requirements, stronger implementation dialogue and the use of Single Market enforcement tools where appropriate. The objective is not to remove legitimate national discretion, but to prevent unnecessary regulatory barriers within the Single Market.

Simplification
Read more
Read more about Gold-plating in practice
News
23 Sep 2026

Europe in a new era of global competition

On Tuesday, 22 September, AmCham EU hosted Dragoș Tudorache, Member of the Cabinet of Executive Vice-President Stéphane Séjourné, European Commission, for a fireside chat. Moderated by Malte Lohan, CEO, AmCham EU, the conversation explored the growing role of economic security in Europe’s trade agenda and external relations. The exchange examined how this shift is shaping the EU’s engagement with trading partners and its position globally. Attention also turned to the choices facing Europe in a changing geo-strategic landscape, including how to reinforce resilience and strengthen competitiveness.

Industry
Simplification
Read more
Read more about Europe in a new era of global competition